相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2005
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- An international task force co-led by Georgetown and University of Maryland experts published consensus recommendations for studying molecular biomarkers in stroke recovery on August 19, 2026, in the International Journal of Stroke. - The framework prioritizes understanding recovery as a biological process rather than a single 90-day outcome, aiming to identify the right treatment for the right patient at the right time. - Candidate biomarkers highlighted include neurofilament light chain (NfL), BDNF, brain-derived tau, GFAP, and interleukin-6, with calls for harmonized longitudinal blood sampling and larger international studies. - The task force stresses that biomarker information must never be used to deny patients access to rehabilitation care.
- An interim analysis of the first-in-human Phase 1 trial of LASSARAB, an inactivated rabies-vectored Lassa fever vaccine, demonstrated 100% seroconversion against both Lassa virus and rabies virus by day 61 in healthy adults. - The vaccine was well tolerated across all dose groups, with no serious adverse events or grade ≥3 reactions; solicited symptoms were predominantly mild and self-limited. - All LASSARAB recipients achieved rabies-neutralizing antibody titers exceeding the WHO correlate of protection (≥0.5 IU/ml), matching responses seen with licensed rabies vaccines. - The study, published in Nature Medicine and conducted at the University of Maryland, supports advancing LASSARAB to larger trials in endemic settings, offering potential dual protection against two priority pathogens.
- The Amish population is doubling roughly every 20 years with a total fertility rate of 6.1 and life expectancy of 81 years, projected to reach nearly 2 million by 2075. - Contrary to political claims, autism does exist among the Amish, though prevalence remains unstudied; vaccination rates vary widely across communities with no centralized church directive. - Amish communities exhibit lower rates of certain cancers and asthma but higher rates of other conditions, offering unique opportunities to study how lifestyle and genetics interact in common diseases. - Most Amish pay for healthcare out-of-pocket through community aid plans and alms, creating distinct challenges for hospital financing and medical research involving this growing population.
- A randomized controlled trial of 180 primary care patients found that five-minute sessions of proximal intercessory prayer significantly reduced both pain and anxiety compared to music control. - Prayer recipients showed greater pain relief immediately and at two weeks, while anxiety improvements persisted for at least six weeks after the intervention. - Black participants experienced particularly large improvements in both pain and anxiety, with 97% of prayer recipients expressing willingness to have prayer available in future medical visits. - The intervention was safe with no adverse events reported, suggesting prayer may serve as a low-cost, non-pharmacologic complement to standard medical care.
- The CREST-2 trial, involving 2,165 patients across 155 sites, found no significant cognitive improvement following carotid revascularization procedures compared to intensive medical therapy alone. - Both carotid endarterectomy and stenting failed to enhance cognitive performance across five neuropsychological assessments measuring learning, attention, memory, and executive function over an average 2.8-year follow-up period. - The findings challenge previous expectations that improving blood flow to the brain through carotid procedures would boost cognitive abilities, even in patients with the poorest baseline cognitive function. - Results suggest that patients with greater than 70% carotid stenosis and diminished cognition may already have irreversible neurologic injury that cannot be restored through revascularization procedures.
- University of Maryland researchers reported encouraging Phase I trial results for an experimental intranasal H5N1 vaccine that triggered broad immune responses against multiple bird flu strains. - The NanoVax H5 intranasal vaccine demonstrated successful mucosal priming and was safe and well-tolerated in 40 healthy adult volunteers over six months. - Participants receiving the adjuvanted vaccine showed strong immune activity including higher protective antibodies, more memory immune cells, and better ability to kill infected cells. - The vaccine's ability to elicit both mucosal and systemic immune responses represents a potential breakthrough for pandemic preparedness and transmission reduction.
- A novel monoclonal antibody called MAM01 provided dose-dependent full protection against malaria infection in a Phase 1 clinical trial with minimal side effects. - The antibody targets a highly conserved region of the Plasmodium falciparum circumsporozoite protein to block infection before it reaches the bloodstream. - All participants who received the highest dose remained infection-free after malaria challenge, while all placebo recipients developed infection. - This breakthrough could transform malaria prevention in vulnerable populations like young children and pregnant women through single-injection, months-long protection.
- Researchers at the University of Maryland completed a successful Phase 1 trial of a novel trivalent Salmonella conjugate vaccine (TSCV) designed to protect against typhoid fever and invasive non-typhoidal Salmonella infections. - The vaccine demonstrated 100% immune response rates in all 22 healthy adult participants, with strong antibody responses persisting over a year after vaccination. - TSCV targets the leading causes of illness and death among children in sub-Saharan Africa, where typhoid fever caused 8,751 deaths and invasive Salmonella caused 66,000 deaths in 2017. - The vaccine was found to be safe and well-tolerated, with only mild injection site pain reported, providing a strong foundation for future pediatric trials in endemic regions.
- University of Maryland researchers have developed ErythroMer, a freeze-dried synthetic blood that can be reconstituted with water in under a minute for emergency transfusions. - The artificial blood uses hemoglobin enclosed in protective fat bubbles to create synthetic red blood cells that remain stable for years at room temperature. - Animal testing shows the synthetic blood can successfully replace up to 90% of blood volume and restore vital signs in hemorrhaging rabbits within minutes. - Human clinical trials are expected to begin within two years, with potential FDA approval and commercial availability in five to eight years.
- The NIH has initiated a Phase 1 clinical trial of LASSARAB, a novel vaccine candidate for Lassa fever, a viral hemorrhagic disease that can be fatal and causes permanent hearing loss in up to one-third of patients. - Developed by researchers at Thomas Jefferson University, LASSARAB demonstrated complete protection in nonhuman primates exposed to lethal doses of Lassa virus, representing a significant advancement in addressing this West African endemic disease. - The trial will enroll 55 healthy adults to evaluate three different concentrations of the vaccine, which uniquely combines protection against both Lassa fever and rabies through a modified inactivated rabies vaccine platform.
